A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...
Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss ...
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...
Lilly said patients taking Zepbound lost about 20% of their weight on average compared with nearly 14% for Wegovy. The drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback